The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy - Scorecard - MDSpire

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

  • By

  • Raffaella Greco

  • Isabel Sánchez-Ortega

  • Antonio M. Risitano

  • Krzysztof Kalwak

  • Annalisa Ruggeri

  • Iliana Kleovoulou

  • Marina Atlija

  • Tobias Alexander

  • Emanuele Angelucci

  • Dina Averbuch

  • Ali Bazarbachi

  • Maria Ester Bernardo

  • Charles Crawley

  • Mette D. Hazenberg

  • Olaf Penack

  • Helen Baldomero

  • Jakob R. Passweg

  • Ibrahim Yakoub-Agha

  • Donal P. McLornan

  • Fabio Ciceri

  • Anna Sureda

  • May 27, 2026

  • 0 min

Share

Clinical Scorecard: EBMT 2024 Activity Report: Surpassing One Million Hematopoietic Cell Transplants and 20,000 CAR-T Therapies – A Milestone in Cellular Treatment

At a Glance

CategoryDetail
ConditionHematological diseases, Immunological disorders, Rheumatic diseases
Key MechanismsHematopoietic cell transplantation (HCT) and CAR-T therapy
Target PopulationPatients with hematological and immunological disorders
Care SettingTransplant centers across Europe and collaborating countries

Key Highlights

  • Over 1 million HCTs reported since 1990, with 47,204 HCTs in 2024.
  • CAR-T therapy reached 6,082 patients in 2024, a 24.5% increase from 2023.
  • Main indications for allo-HCT included myeloid malignancies (62%) and lymphoid malignancies (~24%).
  • Unrelated donor usage increased by 5%, while cord blood use decreased by 6.2%.
  • From 2025, separate reporting for adult and pediatric HCT activity will be implemented.

Guideline-Based Recommendations

Diagnosis

  • Capture detailed information on disease categories and status for HCT and CAR-T therapies.

Management

  • Monitor trends in HCT and CAR-T therapy across participating centers.

Monitoring & Follow-up

  • Establish a comprehensive database to track clinical needs and equitable access.

Risks

  • Pandemic-related declines in transplant activity were mitigated by safety measures.

Patient & Prescribing Data

Patients undergoing hematopoietic cell transplantation and CAR-T therapy.

Increased indications for autoimmune diseases by 67% in CAR-T therapy.

Clinical Best Practices

  • Utilize the EBMT survey for monitoring trends and changes in HCT practices.
  • Incorporate new disease categories for improved reporting granularity.

Related Resources & Content

Original Source(s)

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

  • by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda

  • May 27, 2026

Related Content

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer